Recent laboratory and clinical studies, such as that of Nakagawa et al. and that of Subbiah et al., have revealed new targets and therapeutic treatments centered on EGF family members and their influence on lung cancer angiogenesis [48,49,50]. This evidence concerns the gene EGF and lung cancer.